98%
921
2 minutes
20
Sleep medicine centres play a pivotal role in diagnosing, treating and researching sleep disorders, with structures that range from large, university-based institutions to smaller, community-led clinics. These centres operate at the intersection of clinical care and academic innovation, combining personalised diagnostics and therapy with the evaluation and integration of emerging technologies. As the demand for sleep-related healthcare continues to grow, sleep centres must evolve to accommodate both increasing patient loads and rapid technological advancements. Outpatient departments serve as critical entry points for patients, enabling structured assessments through consultations, questionnaires and objective tools such as actigraphy and home polygraphy. These are increasingly complemented by digital solutions, including telemedicine, automated sleep diaries and remote prescription management. Such tools improve accessibility, streamline workflows and enhance continuity of care. Despite technological progress, sleep laboratories remain indispensable for diagnosing complex disorders like sleep apnea and hypersomnias, where in-lab polysomnography and real-time therapy adjustments are essential. However, advances in portable and wearable devices are creating viable home-based alternatives for selected cases, contributing to reduced lab wait times and broader patient reach. Research and education are foundational to advancing the field. Ongoing updates to sleep medicine curricula, alongside rigorous clinical studies on novel diagnostics and AI tools, ensure that care remains evidence-based and future-ready. Sleep centres, as multidisciplinary hubs, will continue to merge clinical practice, innovation and training-shaping a future where sleep healthcare is more personalised, data-driven and accessible without compromising quality or equity. Together, these developments signal a transformative era in sleep medicine, where integrated, technology-enhanced care will redefine how we understand, diagnose and treat sleep disorders.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jsr.70092 | DOI Listing |
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
JAMA Netw Open
September 2025
School of Rehabilitation Science, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Importance: The cost-effectiveness of adding early in-bed cycling to usual physiotherapy among adults receiving mechanical ventilation in the intensive care unit (ICU) compared with usual physiotherapy alone is unknown.
Objective: To evaluate the cost-effectiveness of in-bed cycling plus usual physiotherapy compared with usual therapy alone in the Critical Care Cycling to Improve Lower Extremity Strength (CYCLE) randomized clinical trial.
Design, Setting, And Participants: This trial-based economic evaluation with a 90-day time horizon compared early cycling plus usual physiotherapy vs usual physiotherapy alone from a societal perspective.
J Telemed Telecare
September 2025
Centre for Innovative Medical Technology, Odense University Hospital, Odense, Denmark.
IntroductionThe use of digital solutions including patient-reported outcomes is limited to follow-up of patients with established diagnoses but is rarely used as first step of the diagnostic process substituting a personal contact with a health professional. We report on the diagnostic validity and cost per patient implications based on a feasibility study of a new virtual diagnostic service (VDS) for common neurological sleep disorders that, as a first step, involves the collection and automated analysis of self-reported digital patient data.MethodsThe VDS was established at the Odense University Hospital, Denmark.
View Article and Find Full Text PDFIntensive Care Med
September 2025
Center for Humanizing the ICU, Beth Israel Deaconess Medical Center, Boston, USA.
J Virol
September 2025
Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, West Bengal, India.
High morbidity and mortality associated with human β-coronavirus (CoV) infection highlight the need to determine host responses to infection and develop anti-viral therapies. Gap junction intercellular communication (GJIC), particularly involving Connexin43 (Cx43), is vital for maintaining central nervous system (CNS) homeostasis, and disruption of GJIC is a well-documented pathogenic mechanism among β-coronaviruses. Specifically, murine β-coronavirus, mouse hepatitis virus (MHV-A59) inoculation in the mouse brain causes acute-stage CNS viral spread and chronic neuroinflammatory demyelination while causing pronounced downregulation of Cx43 at the acute stage, reflecting a critical role in CNS pathology.
View Article and Find Full Text PDF